Angel Publishing's 'Quantum Quake' — The AI Drug Discovery Stock Behind the 300% Claim

The Hook

“World Stunned as ‘AI Doctor’ Produces Cures at Light Speed.” Keith Kohl’s Quantum Quake pitch opens with that headline, then layers on the names: Bill Gates, BlackRock, Citigroup, NVIDIA, all supposedly “loading up” on a “$5 AI Biotech Stock.” The location detail is specific and vivid: a mall in Salt Lake City, “not far from the Panda Express,” where this tiny company worked with NVIDIA to build “the largest and fastest supercomputer in the industry.” The promise: an “AI Doctor” that finds drug candidates 10X faster, at 80% lower cost, with a Phase 2 clinical trial readout that “could easily send shares to $20 or more, a quick 300% gain.”

This is a re-air. The ad first ran in September 2025 and is back in circulation, largely unchanged, because the Phase 2 catalyst it promised 11 months ago hasn’t happened yet. The “secret” stock is Recursion Pharmaceuticals (RXRX), an AI drug discovery company that went public at $18 in 2021 and now trades around $3.27. The service costs $799 a year with a 90-day refund, making this one of the more expensive newsletters we’ve analyzed for a pick that’s down more than 80% from its IPO price.

The Big Claim

Kohl’s thesis rests on a straightforward but powerful idea: artificial intelligence can transform drug discovery the way it transformed image recognition and language processing. Instead of trial-and-error lab work (testing thousands of compounds one at a time), AI models can screen billions of virtual molecules against disease targets in silico, identifying the most promising candidates for human trials. Recursion, with its NVIDIA-powered BioHive supercomputer and partnerships with Roche, Sanofi, Merck, and Bayer, is positioned as the leader.

The numbers sound enormous: 25+ drugs in the pipeline, $455 million in milestone payments already earned, “up to $20 billion more” from Big Pharma partnerships, “5 TIMES its current market cap.” The Phase 2 catalyst is the near-term payoff: positive data from the first AI-discovered cancer treatment could validate the entire platform and re-rate the stock.

The Mechanism

Recursion Pharmaceuticals is a real company doing real science. Founded in 2013, it’s one of the pioneers of technology-enabled drug discovery, what the industry calls “TechBio.” The approach combines automated laboratory robotics (running millions of cellular experiments) with machine learning models that analyze the resulting images and data to identify promising drug candidates.

The NVIDIA partnership provided genuine computing firepower. BioHive-2, built in 2023, was at the time the largest supercomputer in the pharmaceutical industry. The Big Pharma deals are real too: Roche partnered on neuroscience, Bayer on fibrosis, and the milestone payments (while back-end loaded, most of that “$20 billion” only arrives if drugs reach the market) provide non-dilutive funding for the research. The supercomputer is exactly the kind of picks-and-shovels AI infrastructure that’s been attracting capital across the sector.

The merger with Exscientia in 2024 gave Recursion a complementary AI platform and additional pipeline assets. Exscientia had been the first company to get an AI-discovered drug into human trials, a genuine milestone even though that specific drug later failed.

But here’s where the promise hits reality. AI speeds up the drug DISCOVERY phase (finding candidate compounds that might work against a disease target). It does not speed up clinical trials. Once a candidate enters human testing, it faces the same Phase 1 (safety), Phase 2 (efficacy signals), and Phase 3 (large-scale proof) timeline as every other drug. That timeline is 8-10 years from first-in-human to approval. The FDA hasn’t changed its requirements, and patients need to be followed for side effects whether the drug was discovered by AI or by a chemist at a lab bench.

This is the fundamental tension in Kohl’s pitch: he’s promising a quick 300% gain on “just around the corner” Phase 2 data, but the technology he’s excited about delivers its real value over a decade or more.

The Real Pick

Does the Math Check Out?

Kohl’s “300% gain to $20” target implies a roughly $10 billion market cap for Recursion. That’s not impossible; biotech companies with approved drugs and growing revenue routinely command $10-50 billion valuations. But for a pre-revenue company whose lead asset is still in Phase 2, whose AI platform has never produced an approved drug, and whose partner milestone payments are mostly back-end loaded, $10 billion is an aspiration, not a near-term target.

The $20 billion in “potential” milestone payments deserves scrutiny. That figure represents the theoretical maximum if every partnered drug candidate succeeds through Phase 3, wins FDA approval, and achieves commercial milestones. In biotech, roughly 90% of drugs that enter clinical trials fail. Even AI-discovered drugs face the same biological uncertainty. The “$5 billion more than the market cap” framing implies an imminent windfall; the reality is that most of those payments will never materialize.

The comparison to traditional drug development costs (Kohl says AI reduces costs “by up to 80%”) is directionally correct but overstated. AI can reduce the cost of identifying lead candidates (the early discovery phase), but the expensive parts of drug development (Phase 2 and Phase 3 clinical trials, manufacturing scale-up, regulatory filings) remain largely unchanged.

And the track record matters. Kohl previously pitched Exscientia (EXAI) for this same thesis. Exscientia’s AI-discovered cancer drug failed. The company lost its founder to a scandal. It was absorbed by Recursion in what Stock Gumshoe’s Travis Johnson called a “rescue merger.” If you bought EXAI on Kohl’s earlier recommendation and held through the RXRX merger, you’re down roughly 25% while the S&P 500 gained 50% over the same period. The previous AI drug discovery pick didn’t deliver, and the follow-up pick hasn’t either.

What They Got Right

1. AI drug discovery is real technology. Recursion’s BioHive supercomputer, the automated lab robotics, and the machine learning models are genuine scientific infrastructure. This isn’t vaporware.
2. The Big Pharma partnerships are credible. Roche, Bayer, Sanofi, and Merck don’t sign deals with companies they don’t believe have real platforms. That validation matters.
3. NVIDIA’s investment is real. NVIDIA bought roughly 7 million shares in 2023 as part of the BioHive partnership and has held them. This isn’t a pump-and-dump; it’s a strategic computing partnership, one of several NVIDIA side-bets we’ve seen across AI-themed promos.
4. The cost-reduction argument has merit. AI can meaningfully reduce the early-stage cost of identifying drug candidates. Even if “80% cheaper” overstates the total development cost savings, the direction is correct.
5. The pipeline breadth is real. 25+ programs across oncology, neuroscience, and rare disease give multiple shots on goal. Not all will succeed, but the portfolio approach is rational.

What They Got Wrong

1. The timeline is badly misleading. “Just around the corner” Phase 2 data in September 2025 is still “around the corner” in August 2026. Clinical trials take time, and AI doesn’t change that.
2. Kohl’s track record with this thesis is poor. The Exscientia (EXAI) recommendation lost money. The RXRX follow-up has lost roughly 35-45% since the original tease. Two swings, two misses so far.
3. The “$5 billion more than the market cap” milestone framing is standard biotech puffery. Every biotech company with a Big Pharma deal talks about the theoretical maximum milestone payments. Almost none collect more than a fraction of them.
4. RXRX has been a value-destroyer since IPO. It went public at $18, briefly hit $40, and has raised cash by selling shares at lower and lower prices ever since. The dilution has been continuous, and existing shareholders have been diluted with every raise.
5. The “Bill Gates is loading up” framing overstates the connection. The Gates Foundation has made investments in many biotech companies as part of its global health mission. This is not Bill Gates making a personal portfolio bet of the magnitude implied.
6. Re-airing an unchanged ad 11 months later is a red flag. If the Phase 2 catalyst had delivered, Kohl would be running a victory-lap promo, not the same ad with the same “about to happen” urgency.

The Verdict

The technology is real, but the timeline is wrong. Wait for actual clinical data before buying the story.

AI drug discovery is a legitimate technological advance. Recursion, Schrödinger (SDGR), Isomorphic Labs (Alphabet subsidiary), and others are doing genuinely interesting work that could meaningfully improve the speed and success rate of drug development over the coming decade. The NVIDIA partnership, the Big Pharma validation, and the BioHive infrastructure are real assets.

But Kohl is selling this as a near-term catalyst play on “just around the corner” Phase 2 data, and that framing doesn’t match the technology’s timeline. Phase 2 data that was “imminent” in September 2025 still hasn’t arrived in August 2026. The stock has drifted from $5-7 to $3.27, and the company continues to sell shares at lower and lower prices to fund its operations, dilution that directly harms existing shareholders.

At $3.27 with a $1.8 billion market cap, RXRX is cheaper than it was when Kohl first pitched it, and a positive Phase 2 readout could genuinely move the stock. But biotech investing is about managing binary risk: if the data is good, you win; if it’s bad, the stock goes lower still. The right approach is to wait for the data, not to front-run it on a newsletter’s promise that “this time it’s different.”

What would change our view: positive Phase 2 data from RXRX’s lead oncology program, a Big Pharma partner exercising an option to license a specific drug candidate, or meaningful revenue from a partnership deal (not just potential milestone payments). Until then, RXRX is a lottery ticket dressed as an inevitability.

What We’re Watching

• RXRX’s next quarterly filing for updated cash runway, how many quarters before another dilutive raise?
• Phase 2 data from the lead oncology program, the binary event that either validates or breaks the near-term thesis
• Any Big Pharma opt-in or licensing deal, the revenue events that actually move the needle

This is not financial advice. NewsletterVetter has no position in any stock mentioned. Topline Trader’s own disclosures note that biotech investments carry significant risk of total loss, and past performance of Kohl’s recommendations does not guarantee future results. The FDA clinical trial process is lengthy and unpredictable; most drugs that enter trials do not reach the market. Always do your own research before investing.